Myeloproliferative Neoplasms News & Features
Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
A survey-based study investigated the relationship between symptom burden and incidence of medical disability leave among patients with MPNs.
Prevalence, Severity of Psychological Distress Higher in Patients Coping With Philadelphia-negative Myeloproliferative Neoplasm
Researchers sought to determine the prevalence and severity of anxiety and/or depression among patients with Philadelphia-negative MPNs.
Risk of Therapy-Related MDS, AML Increased by Use of Leukemogenic Chemotherapy Agents
Researchers sought to determine the association between chemotherapy, particularly platinum-based agents, and increased risk of tMDS/AML.
No Benefit Achieved With Cytoreductive Therapy for Essential Thrombocythemia With Nonhigh Risk of Thrombosis
A study with more than 2000 patient-years follow-up, researchers found cytoreductive therapy was not as effective in patients with ET who have lower risk for thrombosis.
Recommended Therapies for Polycythemia Vera Underused
Phlebotomy and hydroxyurea tied to improved survival, lower risk for thrombosis in older patients.
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
Results of an open-label phase 2 study demonstrated that a dose-escalation approach can prevent worsening anemia in patients with myelofibrosis undergoing treatment with ruxolitinib.
Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype
In a review of data from DANHES study, researchers determined the hazard ratio for developing myeloproliferative neoplasm — any or by subtype — among smokers, occasional smokers, and ex-smokers, compared with never smokers.
Case Study: Myelofibrosis Diagnosis and Early Intervention
In this Case Study, Ms Lyle discusses diagnosis and early management of myelofibrosis in a 72-year-old male patient.
Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
In the EBMT ALWP study, researchers sought to determine the efficacy of myeloablative conditioning to reduce the risk for post allogeneic HCT in patients with sAML without significantly increasing non-relapse mortality.
Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome
A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Nurse-Led vs Oncologist-Led Breast Cancer Follow-up Program: Early Feasibility Results of an Ongoing Study
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Identifying the Needs of Multidisciplinary Team Treating Geriatics Cancer Patients
- Hypofractionated Radiotherapy for Prostate Cancer: The New ASTRO/ASCO/AUA Guideline
- Risk of Hospitalization Remains High for Survivors of Childhood Leukemia
- Sequence of Immunotherapy, Targeted Therapy, Radiation Therapy Influences Overall Survival in Melanoma Brain Metastases
- Survey Demonstrates Implicit Bias Toward Cervical Cancer Diagnoses Among Nurses, Women
- Use of Watchful Waiting Up for Low-Risk Localized Prostate Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |